Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA

Journal of Infectious Diseases

Volumn 190, Issue 10, 2004, Pages 1841-1849

  Ashkar, Ali A ^a,b   Yao, Xiao Dan ^a   Gill, Navkiran ^a   Sajic, Dusan ^a   Patrick, Amy J ^a   Rosenthal, Kenneth L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA; DOUBLE STRANDED RNA; LIGAND; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 LIGAND; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 LIGAND; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE EXPRESSION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENOMEGALY; VAGINA MUCOSA;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; INTERFERON TYPE II; LIGANDS; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MUCOUS MEMBRANE; OLIGODEOXYRIBONUCLEOTIDES; PLAQUE ASSAY; POLY I-C; RECEPTORS, CELL SURFACE; RNA, DOUBLE-STRANDED; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TRANSCRIPTION, GENETIC; VAGINA;

EID: 8444247042     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425079     Document Type: Article

References (35)

1. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74:479-85.
2. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
3. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16:637-46.
4. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000; 343:338-44.
5. Ashkar AA, Rosenthal KL. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med 2002; 2:545-56.
6. Chuang T, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 2001; 1518:157-61.
7. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85:85-95.
8. Medzhitov R, Janeway CA Jr. An ancient system of host defense. Curr Opin Immunol 1998; 10:12-5.
9. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 2002; 27:474-82.
10. Takeuchi O, Akira S. MyD88 as a bottle neck in Toll/IL-1 signaling. Curr Top Microbiol Immunol 2002; 270:155-67.
11. Dalpke A, Heeg K. Signal integration following Toll-like receptor triggering. Crit Rev Immunol 2002; 22:217-50.
12. Hertzog PJ, O'Neill LA, Hamilton JA. The interferon in TLR signaling: more than just antiviral. Trends Immunol 2003; 24:534-9.
13. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8.
14. Doyle S, Vaidya S, O'Connell R, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002; 17:251-63.
15. Doyle SE, O'Connell R, Vaidya SA, Chow EK, Yee K, Cheng G. Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J Immunol 2003; 170:3565-71.
16. Fitzgerald KA, Rowe DC, Barnes BJ, et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003; 198:1043-55.
17. Kaisho T, Hoshino K, Iwabe T, Takeuchi O, Yasui T, Akira S. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation. Int Immunol 2002; 14:695-700.
18. Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol 2003; 77:8948-56.
19. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003; 77:953-62.
20. Pyles RB, Higgins D, Chalk C, et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 2002; 76:11387-96.
21. Gao JJ, Diesl V, Wittmann T, et al. Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol 2002; 72:1234-45.
22. McDermott MR, Smiley JR, Leslie P, Brais J, Rudzroga HE, Bienenstock J. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 1984; 51:747-53.
23. Docherty JJ, Lohse MA, Dellaria MF, et al. Incidence of herpes simplex virus types 1 and 2 in penile lesions of college men. J Med Virol 1984; 13:163-70.
24. Sajic D, Ashkar AA, Patrick AJ, et al. Parameters of CpG oligodeoxy-nucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol 2003; 71:561-8.
25. Vaidya SA, Cheng G. Toll-like receptors and innate antiviral responses. Curr Opin Immunol 2003; 15:402-7.
26. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
27. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001; 75:10730-7.
28. Rassa JC, Meyers JL, Zhang Y, Kudaravalli R, Ross SR. Murine retroviruses activate B cells via interaction with Toll-like receptor 4. Proc Natl Acad Sci USA 2002; 99:2281-6.
29. Bieback K, Lien E, Klagge IM, et al. Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J Virol 2002; 76:8729-36.
30. Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalo-virus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003; 77:4588-96.
31. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200.
32. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2002; 195:559-70.
33. Davila E, Velez MG, Heppelmann CJ, Celis E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood 2002; 100:2537-45.
34. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10:187-92.
35. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003; 19:837-47.